| 101 |
31411498 | Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus. | 2020 Jan |
1 |
| 102 |
31608548 | Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. | 2020 Mar |
4 |
| 103 |
31955491 | Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. | 2020 Jul |
3 |
| 104 |
31995840 | Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing. | 2020 Mar |
5 |
| 105 |
32011961 | Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer. | 2020 Feb |
2 |
| 106 |
32037850 | Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar). | 2020 Sep |
4 |
| 107 |
32118347 | Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study. | 2020 Sep |
1 |
| 108 |
32130661 | Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V). | 2020 Apr |
1 |
| 109 |
32160049 | RISK FACTORS FOR HYPOGLYCEMIA IN INPATIENTS WITH TOTAL PARENTERAL NUTRITION AND TYPE 2 DIABETES: A POST HOC ANALYSIS OF THE INSUPAR STUDY. | 2020 Jun 2 |
1 |
| 110 |
32210600 | Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study. | 2020 |
3 |
| 111 |
32215829 | MYL1501D Insulin Glargine: A Review in Diabetes Mellitus. | 2020 Apr |
11 |
| 112 |
32220551 | Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c. | 2020 Jul |
2 |
| 113 |
32271092 | Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study. | 2020 Jun |
2 |
| 114 |
32277401 | Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis. | 2020 May |
1 |
| 115 |
32291880 | Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial. | 2020 Sep |
1 |
| 116 |
32295808 | Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial. | 2020 Jun |
1 |
| 117 |
32308446 | Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. | 2020 |
2 |
| 118 |
32313609 | Glargine-300: An updated literature review on randomized controlled trials and real-world studies. | 2020 Apr 15 |
3 |
| 119 |
32314521 | Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial. | 2020 Sep |
1 |
| 120 |
32315508 | Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues. | 2020 Apr 21 |
2 |
| 121 |
32318639 | Insulin/carbohydrates ratio during the first 6-month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study. | 2020 Apr |
2 |
| 122 |
32337298 | Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study. | 2020 |
2 |
| 123 |
32342025 | Case Report: High-concentration Insulin Glargine Overdose Complicated by Hepatic Steatosis. | 2020 May 1 |
3 |
| 124 |
32350009 | Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project. | 2020 Apr 28 |
1 |
| 125 |
32360709 | Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. | 2020 Aug |
1 |
| 126 |
32388224 | Development of a robust functional cell-based assay for replacing the rabbit blood sugar bioidentity test of insulin glargine drug substance. | 2020 Jul 15 |
1 |
| 127 |
32397452 | The Characteristics of Care Provided to Population(s) in Precarious Situations in 2015. A Preliminary Study on the Universal Health Cover in France. | 2020 May 9 |
1 |
| 128 |
32399816 | Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus. | 2020 Aug |
2 |
| 129 |
32403130 | Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. | 2020 Aug 1 |
1 |
| 130 |
32412055 | National trends in prescription drug expenditures and projections for 2020. | 2020 Jul 23 |
1 |
| 131 |
32419872 | The Charcot Neuroarthropathy as Onset of Type 2 Diabetes - a Diagnostic Challenge. | 2020 Mar |
1 |
| 132 |
32515543 | Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials. | 2020 Oct |
1 |
| 133 |
32520154 | Underutilization of insulin and better metabolic control. A NOVA clinic experience. | 2020 Mar |
1 |
| 134 |
32527798 | Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018). | 2020 Aug |
7 |
| 135 |
32543316 | Determination of amyloid core regions of insulin analogues fibrils. | 2020 Jan 1 |
1 |
| 136 |
32595277 | Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. | 2020 |
2 |
| 137 |
32606850 | Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia. | 2020 |
1 |
| 138 |
32643130 | Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study. | 2020 Aug |
1 |
| 139 |
32651837 | Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes. | 2020 Aug |
1 |
| 140 |
32681460 | Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. | 2020 Sep |
1 |
| 141 |
32694215 | Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. | 2020 Oct |
2 |
| 142 |
32700442 | Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. | 2020 Nov |
2 |
| 143 |
32729217 | A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. | 2020 Nov |
1 |
| 144 |
32753920 | Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland. | 2020 |
3 |
| 145 |
32798057 | Efficacy and Safety of Commonly Used Insulin Analogues in the Treatment of Diabetic Ketoacidosis: A Bayesian Indirect Treatment Comparison. | 2020 Aug |
1 |
| 146 |
32813262 | Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study. | 2020 Oct |
1 |
| 147 |
32963612 | Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro. | 2020 Nov |
1 |
| 148 |
32966971 | Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease. | 2020 |
1 |
| 149 |
32975710 | The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review. | 2020 Nov |
1 |
| 150 |
32984519 | A UNIQUE CASE OF ATEZOLIZUMAB-INDUCED AUTOIMMUNE DIABETES. | 2020 Jan-Feb |
1 |